Reversion Of Oxaliplatin Resistance In Colon Carcinoma Cells By Down-regulation Of The REV3L

Objective To assess the effects of down-regulating a human translesion DNA synthesis(TLS)gene REV3 L on sensitizing drug-resistant tumor cells for chemotherapy.Methods The study experimentally suppressed the REV3 L expression in human Oxaliplatin resistant colon cancer cells(THC8307/L-OHP) by the interference RNA technology(RNAi).Real-time q PCR and Immunocytochemistry can be used for judging the transfection efficiency by RNAi. The level of drug sensitivity was measured by MTT(Thiazolyl blue tetrazolium bromide). The resistance index(RI) and relative reversion of drug resistance are calculated by statistical methods. The cell apoptosis of was determined by flow cytometry and cytomorphology.Results THC8370/L-OHP cells transfected with m U6pro-si REV3 significantly reduced the cellular REV3 L m RNA and protein levels, as judged by q RT-PCR and immunocytochemistry respectively. The IC50(Inhibitory Concentration 50) by Oxaliplatin and the RI were markedly decreased. Depletion of cellular REV3 L also enhanced apoptosis(P<0.05).Conclusion Depletion of REV3 L from Oxaliplatin-resistant human colon cancer cells enhances the drug-sensitivity and induces apoptosis. Hence, REV3 L is one of a potential target for tumor gene therapy.